Search Results for: Benign Prostatic Hyperplasia Treatment Market
Articles
September 16, 2015
Benign Prostatic Hyperplasia Treatment Market Value to Reach Nearly $5 Billion September 16, 2015
The value of the global therapeutics market for Benign Prostatic Hyperplasia (BPH) will rise from just over $2 billion in...
June 14, 2023
Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas June 14, 2023
Blue Water Biotech, Inc. recently announced the signing of an Asset Purchase Agreement with WraSer, LLC and Xspire Pharma, LLC for the purchase of six FDA-approved assets across multiple indications, including cardiology, otic infections, and pain….
April 24, 2023
Blue Water Vaccines Announces Corporate Name Change to Blue Water Biotech in Connection With Transition Into Commercial-Stage Biotechnology Company April 24, 2023
Blue Water Vaccines Inc. recently announced it has changed its corporate name to Blue Water Biotech, Inc. The corporate name...
October 13, 2021
Veru Enrolls First Patient in International Phase 3 ARTEST Clinical Trial of Enobosarm in Metastatic Breast Cancer October 13, 2021
Veru Inc. recently announced it has enrolled the first patient in its Phase 3 ARTEST registration trial of enobosarm, an...
September 21, 2021
Veru Announces Positive Updated Data from Phase 1b/2 Sabizabulin Study in Men With Metastatic Castration-Resistant Prostate Cancer September 21, 2021
Veru Inc. recently announced that updated clinical data from the positive Phase 1b/2 study of sabizabulin (VERU-111) in 80 men...
June 29, 2021
Veru Announces the Presentation of a Phase 1b/2 Clinical Study Update for Sabizabulin June 29, 2021
Veru Inc. recently announced updated clinical results from the ongoing Phase 1b/2 clinical study of sabizabulin (VERU-111), an oral cytoskeleton...
March 4, 2021
Veru Receives FDA Agreement to Advance VERU-111 Into Phase 3 Study March 4, 2021
Veru Inc. recently announced the FDA agreed in an End of Phase 2 meeting, to advance VERU-111 into a Phase 3 registration clinical study based on the clinically meaningful benefits observed with….
September 29, 2020
Veru Completes Enrollment of Phase 2 Clinical Trial of Novel Oral Drug September 29, 2020
Veru Inc. recently announced it has fully enrolled its Phase 2 clinical study of VERU-111, its novel, oral, alpha and...
August 23, 2016
Female Health Company & Aspen Park Pharmaceuticals Announce FDA Clears Pathway August 23, 2016
The Female Health Company (FHC) and Aspen Park Pharmaceuticals, Inc. (APP) recently announced that the US FDA has agreed to...
January 13, 2015
Frost & Sullivan Releases Drug Launch Phase III Trial Watch List for Top Therapeutic Areas January 13, 2015
The therapeutics market is buzzing with activity, as several promising therapies are progressing to Phase III clinical trials and many...
February 16, 2012
2/21/2012 February 16, 2012
Catalent Pharma Solutions & NewMarket Sign Development Agreement Catalent Pharma Solutions and NewMarket Pharmaceuticals LLC recently announced they have entered...
February 16, 2012
IntelGenx Announces License Agreement With Edgemont Pharmaceuticals February 16, 2012
IntelGenx Corp. recently announced it has entered into an exclusive agreement with Edgemont Pharmaceuticals, LLC for the commercialization of IntelGenx's...
